Subscribe to Search results

AIDS discussed at Heathrow hotel meeting of haemophilia centre directors.

Published on:

Professor Bloom reported to CDSC a "probable" case of AIDS in one of his patients.

Published on:

Special meeting of reference centre directors discussed AIDS.

Published on:

Letter from Professor Bloom and Dr Rizza set out general recommendations for treatment agreed at the 13 May 1983 special meeting.

Published on:

Professor Bloom told UKHCDO meeting that there was "no proof that commercial concentrates were the cause of AIDS"; meeting agreed that patients "should not be encouraged to go over to cryoprecipitate for home therapy".

Published on:

UKHCDO released AIDS Advisory Document.

Published on:

Five commercial Factor 8 products (Hemofil, Kryobulin, Profilate, Factorate and Koate) were granted licences in the UK.

Published on:

World in Action: Blood Money was broadcast on television in the UK.

Published on:

The Food and Drug Administration inspection regime for plasma centres commenced in the US.

Published on:

The Morbidity and Mortality Weekly Report reported that three people with haemophilia had contracted AIDS in the US.

Published on:

Alpha informed the Food and Drug Administration it would not be using plasma from hyperimmunised donors for factor concentrate manufacture.

Published on:

A memo from Dr John Hink of Cutter recorded his intention that remaining high titre plasma, dating from July 1982, would be processed in experimental products that would not be for human use.

Published on:

Pharmaceutical companies started excluding high risk donors (especially male homosexuals, intravenous drug users).

Published on:

A public meeting was held in Atlanta at the instigation of Centers for Disease Control to discuss AIDS.

Published on:

Alpha issued a press release warning of a real risk of AIDS from taking Factor 8 concentrates.

Published on:

Dr John Petricciani of the Food and Drug Administration sent a letter to all Licensed Manufacturers of Plasma Derivatives recommending excluding high risk plasma from blood products.

Published on:

The US Blood Products Advisory Committee discussed product recall and concluded it should be decided on a case-by-case basis.

Published on:

Notes on Transfusion by Ministry of Health warned of risks of transfusion.

Published on:

A parent of a Treloar's student provided consent for their son to take part in a DDAVP trial but asked for further information about this "other substance".

Published on:

In 1976 over 600,000 units of cryoprecipitate, just over 150,000 units of NHS Factor 8 and over 1,000,000 units of three different commercial concentrates were used at Treloar's.

Published on: